In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “operation summary” containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying party, which is solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups concerned:<\/strong><\/p>\n Nature of the operation <\/strong><\/p>\n Economic sectors concerned <\/strong><\/p>\n Deadline for interested third parties to submit their observations <\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration operation concerning the exclusive takeover by the company \u201cPharma Capital SA\u201d of the companies \u201cAfric-Phar SA\u201d, \u201cPharmis SA\u201d, and \u201cPartner Lab SA\u201d through the respective acquisition of 95.35%, 55%, and 4% of their share capital and associated voting rights.<\/p>\n \u201cPharma Capital\u201d is a Moroccan joint-stock company, with its registered office at 29, rue de Lille, 2nd floor, Roches Noires, Casablanca, Morocco, registered with the Casablanca Trade Register under number 625427, specializing in investment in the pharmaceutical sector.<\/p>\n \u201cAfric-Phar\u201d is a Moroccan joint-stock company, with its registered office at 134 All\u00e9e des Mimosas, Ain Sebaa, Casablanca, Morocco, registered with the Casablanca Trade Register under number 29767, engaged in the production and distribution of pharmaceutical products.<\/p>\n \u201cPharmis\u201d is a Moroccan joint-stock company, with its registered office at 134, all\u00e9e des Mimosas, A\u00efn Seba\u00e2, Casablanca, Morocco. It specializes in the production and distribution of pharmaceutical products.<\/p>\n \u201cPartner Lab\u201d is a Moroccan joint-stock company, with its registered office at Route R\u00e9gionale Casablanca – Mohammedia N\u00b0322, Km 10.5 Lotissement Est A\u00efn Seba\u00e2, Lot N\u00b01, A\u00efn Seba\u00e2 20590, Casablanca, Morocco, specializing in pharmaceutical research and development.<\/p>\n <\/p>\n Done in Rabat on November 7, 2024.<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “operation summary” containing the information provided by the parties. This information has been prepared by the notifying party, which is solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups concerned: The acquirer: Pharma Capital SA; The target companies: Afric-Phar SA, Pharmis SA, and Partner Lab SA. Nature of the operation Exclusive takeover. Economic sectors concerned The pharmaceutical products sector. Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e. November 21, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration operation concerning the exclusive takeover by the company \u201cPharma Capital SA\u201d of the companies \u201cAfric-Phar SA\u201d, \u201cPharmis SA\u201d, and \u201cPartner Lab SA\u201d through the respective acquisition of 95.35%, 55%, and 4% of their share capital and associated voting rights. \u201cPharma Capital\u201d is a Moroccan joint-stock company, with its registered office at 29, rue de Lille, 2nd floor, Roches Noires, Casablanca, Morocco, registered with the Casablanca Trade Register under number 625427, specializing in investment in the pharmaceutical sector. \u201cAfric-Phar\u201d is a Moroccan joint-stock company, with its registered office at 134 All\u00e9e des Mimosas, Ain Sebaa, Casablanca, Morocco, registered with the Casablanca Trade Register under number 29767, engaged in the production and distribution of pharmaceutical products. \u201cPharmis\u201d is a Moroccan joint-stock company, with its registered office at 134, all\u00e9e des Mimosas, A\u00efn Seba\u00e2, Casablanca, Morocco. It specializes in the production and distribution of pharmaceutical products. \u201cPartner Lab\u201d is a Moroccan joint-stock company, with its registered office at Route R\u00e9gionale Casablanca – Mohammedia N\u00b0322, Km 10.5 Lotissement Est A\u00efn Seba\u00e2, Lot N\u00b01, A\u00efn Seba\u00e2 20590, Casablanca, Morocco, specializing in pharmaceutical research and development. Done in Rabat on November 7, 2024.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40434","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n